Novo has long sold a separate version of oral semaglutide for diabetes under the brand name Rybelsus, which the medicine ...

In the fiercely competitive inflammatory bowel disease (IBD) market, Eli Lilly is making the case for its antibody Omvoh as a ...

Central to the new report (PDF) are the JEC Democrats' findings that Trump increased his stock holdings in the pharmaceutical ...

U.S.-based generic drugmaker Par Health has issued a voluntary recall of 22 lots of the direct thrombin inhibitor argatroban ...

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into ...

In this week's episode of "The Top Line," we're looking at two companies building on recent successes and pursuing new ...

Sanofi is gearing up for another major sports sponsorship in its home country, this time with the 2027 Tour de France. | The ...

Martin Shkreli is back in the Federal Trade Commission’s spotlight, this time for allegedly violating his l | The FTC alleges ...

Hot off a pair of key FDA green lights this summer, rare disease specialist Ultragenyx has wasted little time cashing in a ...

Since the drug’s approval and launch earlier this year, J&J has recorded more than 20,000 patient starts on Icotyde, funneled ...

Some six years after scoring an initial FDA nod in neuromyelitis optica spectrum disorder, Roche’s IL-6 receptor agonist ...

With a Friday go-ahead from the FDA, another key piece of Teva’s innovation revamp strategy has fallen into place, further ...